This is a non-core endpoint: only basic statistics are computed.
Burn and corrosion, body region unspecified
ST19_BURN_CORROSION_BODY_REGION_UNSPE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
224 |
4. Check minimum number of eventsNone |
224 |
5. Include endpointsNone |
224 |
6. Filter based on genotype QC (FinnGen only) |
217 |
Control definitions (FinnGen only)
- Control exclude
- CD2_BENIGN_FEMALE_GEN_OTH
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- T29|T3[0-2]
- Name in latin
- Combustiones et corrosiones regione corporis non specificata
Similar endpoints
↥List of similar endpoints to
Burn and corrosion, body region unspecified
based on the number of shared cases.
Similar with more cases:
- Burns and corrosions
- Injury, poisoning and certain other consequences of external causes
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 217 | 100 | 117 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.05 |
| Median age at first event (years) | 49.35 | 44.27 | 53.68 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 224
- Matched controls
- 2240
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
T30.0
ICD-10 Finland
Burn of unspecified body region, unspecified degree
1230.0
161.8
139
*
S14
ICPC
Burn/scald
22.8
77.6
62
37
T30.2
ICD-10 Finland
Burn of second degree, body region unspecified
+∞
53.3
49
*
X12
ICD-10 Finland
Contact with other hot fluids
80.6
36.4
40
6
T30.1
ICD-10 Finland
Burn of first degree, body region unspecified
+∞
25.5
24
*
SPAT1148
SPAT
Treatment of chronic ulcer or burn
5.0
21.1
54
134
T21.2
ICD-10 Finland
Burn of second degree of trunk
+∞
19.0
18
*
X18
ICD-10 Finland
Contact with other hot metals
109.3
18.9
20
*
X59
ICD-10 Finland
Exposure to unspecified factor
3.2
13.7
73
296
ZZA00
NOMESCO Finland
Split skin graft
13.6
11.9
20
16
X19
ICD-10 Finland
Contact with other and unspecified heat and hot substances
68.7
11.7
13
*
QDD20
NOMESCO Finland
Excision of burn of lower limb and coverage
37.1
11.4
14
*
QDD00
NOMESCO Finland
Dressing of major burn of lower limb
45.7
11.0
13
*
T24.2
ICD-10 Finland
Burn of second degree of hip and lower limb, except ankle and foot
29.7
10.9
14
5
T31.0
ICD-10 Finland
Burns involving less than 10% of body surface
42.1
10.1
12
*
T22.2
ICD-10 Finland
Burn of second degree of shoulder and upper limb, except wrist and hand
27.4
9.9
13
5
QCD00
NOMESCO Finland
Dressing of major burn of upper limb
38.4
9.1
11
*
W92
ICD-10 Finland
Exposure to excessive heat of man-made origin
52.1
8.7
10
*
QBD20
NOMESCO Finland
Excision of burn of trunk and coverage
93.4
8.5
9
*
T21.1
ICD-10 Finland
Burn of first degree of trunk
+∞
8.4
8
*
T23.2
ICD-10 Finland
Burn of second degree of wrist and hand
12.3
8.2
14
12
T30
ICD-10 Finland
Burn and corrosion, body region unspecified
+∞
7.3
7
*
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
3.1
7.2
33
120
X58
ICD-10 Finland
Exposure to other specified factors
2.5
6.9
49
224
A46
ICD-10 Finland
Erysipelas
2.6
6.6
42
182
T21.0
ICD-10 Finland
Burn of unspecified degree of trunk
71.8
6.5
7
*
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.8
6.3
34
135
T31.1
ICD-10 Finland
Burns involving 10-19% of body surface
+∞
6.3
6
*
SPAT1312
SPAT
General health counselling
2.1
6.1
80
472
T36
ICD-10 Finland
Poisoning by systemic antibiotics
3.9
6.1
18
49
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Psychiatry
26 [38004469]
26 [38004469]
1.3e+00
1.4e+00
1.7e+00
—
2.3e+00
1.6e+00
1.1e+00
cases:17.65%
controls:5.50%
cases:9.50%
controls:2.63%
cases:5.43%
controls:1.00%
—
—
cases:8.14%
controls:0.86%
cases:11.52%
controls:2.52%
cases:16.02%
controls:5.72%
39
121
182
2081
21
58
200
2144
12
22
209
2180
—
18
19
203
2182
25
55
192
2129
29
105
152
1732
Emergency Room Visit
ER [9203]
ER [9203]
6.3e-01
7.8e-01
2.1e+00
—
2.3e+00
8.9e-01
8.6e-01
cases:47.51%
controls:32.52%
cases:20.36%
controls:10.54%
cases:9.50%
controls:1.32%
—
—
cases:12.22%
controls:1.32%
cases:21.66%
controls:10.21%
cases:45.86%
controls:26.46%
105
716
116
1486
45
232
176
1970
21
29
200
2173
—
27
29
194
2172
47
223
170
1961
83
486
98
1351
General Practice
1 [38004446]
1 [38004446]
8.0e-01
1.0e+00
1.6e+00
1.0e+50
2.7e+00
1.2e+00
5.8e-01
cases:23.08%
controls:11.90%
cases:11.76%
controls:4.59%
cases:4.07%
controls:0.86%
cases:26.24%
controls:0.00%
cases:7.24%
controls:0.55%
cases:15.67%
controls:5.31%
cases:20.44%
controls:12.57%
51
262
170
1940
26
101
195
2101
9
19
212
2183
58
0
163
2202
16
12
205
2189
34
116
183
2068
37
231
144
1606
cefalexin; oral
J01DB01 [21602870]
J01DB01 [21602870]
3.0e-01
8.7e-01
1.7e+00
—
3.0e+00
6.0e-01
8.6e-01
cases:33.48%
controls:27.11%
cases:18.55%
controls:8.72%
cases:4.07%
controls:0.77%
—
—
cases:13.12%
controls:0.73%
cases:14.75%
controls:8.70%
cases:45.86%
controls:26.29%
74
597
147
1605
41
192
180
2010
9
17
212
2185
—
29
16
192
2185
32
190
185
1994
83
483
98
1354
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
5.3e-02
2.3e-01
8.7e-01
3.6e+00
1.4e+00
2.5e-01
2.4e-01
cases:36.65%
controls:35.42%
cases:33.94%
controls:28.88%
cases:12.67%
controls:5.72%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.13%
cases:35.94%
controls:30.31%
cases:55.80%
controls:49.81%
81
780
140
1422
75
636
146
1566
28
126
193
2076
21
6
200
2196
47
135
174
2066
78
662
139
1522
101
915
80
922
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
3.6e-02
2.2e-01
8.7e-01
3.6e+00
1.4e+00
2.5e-01
2.5e-01
cases:36.20%
controls:35.38%
cases:33.48%
controls:28.79%
cases:12.67%
controls:5.72%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.94%
controls:30.31%
cases:55.80%
controls:49.48%
80
779
141
1423
74
634
147
1568
28
126
193
2076
21
6
200
2196
47
136
174
2065
78
662
139
1522
101
909
80
928
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
5.5e-02
2.3e-01
8.6e-01
3.6e+00
1.4e+00
2.6e-01
2.4e-01
cases:36.65%
controls:35.38%
cases:33.94%
controls:28.88%
cases:12.67%
controls:5.77%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.94%
controls:30.22%
cases:55.80%
controls:49.81%
81
779
140
1423
75
636
146
1566
28
127
193
2075
21
6
200
2196
47
136
174
2065
78
660
139
1524
101
915
80
922
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
5.3e-02
2.3e-01
8.6e-01
3.6e+00
1.4e+00
2.5e-01
2.4e-01
cases:36.65%
controls:35.42%
cases:33.94%
controls:28.88%
cases:12.67%
controls:5.77%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.94%
controls:30.31%
cases:55.80%
controls:49.81%
81
780
140
1422
75
636
146
1566
28
127
193
2075
21
6
200
2196
47
136
174
2065
78
662
139
1522
101
915
80
922
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
5.1e-02
2.3e-01
8.6e-01
3.6e+00
1.4e+00
2.6e-01
2.4e-01
cases:36.65%
controls:35.47%
cases:33.94%
controls:28.88%
cases:12.67%
controls:5.77%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.94%
controls:30.22%
cases:55.80%
controls:49.81%
81
781
140
1421
75
636
146
1566
28
127
193
2075
21
6
200
2196
47
136
174
2065
78
660
139
1524
101
915
80
922
Emergency Medicine
93 [38004510]
93 [38004510]
5.8e-01
8.6e-01
2.3e+00
1.0e+50
2.1e+00
7.1e-01
5.3e-01
cases:20.81%
controls:12.81%
cases:15.84%
controls:7.36%
cases:10.86%
controls:1.23%
cases:29.41%
controls:0.00%
cases:8.60%
controls:1.18%
cases:15.21%
controls:8.10%
cases:29.83%
controls:20.03%
46
282
175
1920
35
162
186
2040
24
27
197
2175
65
0
156
2202
19
26
202
2175
33
177
184
2007
54
368
127
1469
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
4.9e-02
2.3e-01
8.5e-01
3.6e+00
1.4e+00
2.3e-01
2.4e-01
cases:36.65%
controls:35.51%
cases:33.94%
controls:29.02%
cases:12.67%
controls:5.81%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.48%
controls:30.49%
cases:55.80%
controls:49.92%
81
782
140
1420
75
639
146
1563
28
128
193
2074
21
6
200
2196
47
136
174
2065
77
666
140
1518
101
917
80
920
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
5.1e-02
2.3e-01
8.5e-01
3.6e+00
1.4e+00
2.5e-01
2.4e-01
cases:36.65%
controls:35.47%
cases:33.94%
controls:28.93%
cases:12.67%
controls:5.86%
cases:9.50%
controls:0.27%
cases:21.27%
controls:6.18%
cases:35.94%
controls:30.45%
cases:55.80%
controls:49.92%
81
781
140
1421
75
637
146
1565
28
129
193
2073
21
6
200
2196
47
136
174
2065
78
665
139
1519
101
917
80
920
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
SPAT1148 [2001700249]
7.7e-01
1.5e+00
—
—
4.0e+00
1.7e+00
6.8e-01
cases:3.17%
controls:1.50%
cases:2.26%
controls:0.50%
—
—
—
—
cases:15.38%
controls:0.32%
cases:4.61%
controls:0.87%
cases:2.76%
controls:1.42%
7
33
214
2169
5
11
216
2191
—
—
34
7
187
2194
10
19
207
2165
5
26
176
1811
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
1.1e-01
1.2e-01
5.7e-01
3.9e+00
1.2e+00
9.6e-02
-4.0e-02
cases:63.80%
controls:61.17%
cases:57.47%
controls:54.63%
cases:33.48%
controls:22.16%
cases:32.58%
controls:1.00%
cases:49.77%
controls:22.49%
cases:60.37%
controls:58.06%
cases:72.93%
controls:73.71%
141
1347
80
855
127
1203
94
999
74
488
147
1714
72
22
149
2180
110
495
111
1706
131
1268
86
916
132
1354
49
483
Emergency Room and Inpatient Visit
ERIP [262]
ERIP [262]
5.5e-01
1.1e+00
1.7e+00
1.0e+50
2.8e+00
7.8e-01
4.0e-01
cases:8.14%
controls:4.86%
cases:6.33%
controls:2.23%
cases:3.62%
controls:0.68%
cases:4.52%
controls:0.00%
cases:4.52%
controls:0.27%
cases:7.37%
controls:3.53%
cases:12.15%
controls:8.49%
18
107
203
2095
14
49
207
2153
8
15
213
2187
10
0
211
2202
10
6
211
2195
16
77
201
2107
22
156
159
1681
Inpatient Hospital
21 [8717]
21 [8717]
4.0e-01
8.8e-01
1.8e+00
1.0e+50
2.1e+00
3.1e-01
6.0e-01
cases:39.37%
controls:30.25%
cases:16.74%
controls:7.72%
cases:4.98%
controls:0.86%
cases:15.84%
controls:0.00%
cases:9.95%
controls:1.32%
cases:10.60%
controls:7.97%
cases:30.94%
controls:19.71%
87
666
134
1536
37
170
184
2032
11
19
210
2183
35
0
186
2202
22
29
199
2172
23
174
194
2010
56
362
125
1475
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-4.5e-01
—
-1.0e+50
—
—
2.1e+00
3.2e+00
cases:19.91%
controls:27.97%
—
—
cases:0.00%
controls:0.68%
—
—
—
—
cases:4.15%
controls:0.55%
cases:18.23%
controls:0.93%
44
616
177
1586
—
0
15
221
2187
—
—
9
12
208
2172
33
17
148
1820
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
2.0e-01
2.9e-01
8.5e-01
3.5e+00
1.5e+00
3.5e-01
1.9e-01
cases:31.22%
controls:27.07%
cases:24.43%
controls:19.53%
cases:9.05%
controls:4.09%
cases:7.24%
controls:0.23%
cases:15.84%
controls:3.95%
cases:26.73%
controls:20.51%
cases:41.99%
controls:37.40%
69
596
152
1606
54
430
167
1772
20
90
201
2112
16
5
205
2197
35
87
186
2114
58
448
159
1736
76
687
105
1150
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
7.7e-02
1.8e-01
7.7e-01
3.2e+00
1.1e+00
2.4e-01
7.7e-02
cases:41.63%
controls:39.78%
cases:41.18%
controls:36.97%
cases:20.36%
controls:10.58%
cases:11.76%
controls:0.54%
cases:26.24%
controls:10.77%
cases:45.16%
controls:39.38%
cases:58.01%
controls:56.12%
92
876
129
1326
91
814
130
1388
45
233
176
1969
26
12
195
2190
58
237
163
1964
98
860
119
1324
105
1031
76
806
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
1.9e-01
9.7e-01
1.7e+00
—
1.5e+00
5.0e-01
7.2e-01
cases:11.31%
controls:9.54%
cases:10.41%
controls:4.22%
cases:4.52%
controls:0.86%
—
—
cases:4.52%
controls:1.00%
cases:7.83%
controls:4.90%
cases:20.44%
controls:11.16%
25
210
196
1992
23
93
198
2109
10
19
211
2183
—
10
22
211
2179
17
107
200
2077
37
205
144
1632
Outpatient Visit
OP [9202]
OP [9202]
1.9e-01
2.6e-01
4.2e-01
2.7e+00
1.5e+00
5.3e-01
4.4e-01
cases:72.40%
controls:68.53%
cases:53.85%
controls:47.37%
cases:14.48%
controls:10.04%
cases:6.79%
controls:0.50%
cases:32.13%
controls:9.36%
cases:61.29%
controls:48.26%
cases:81.22%
controls:73.65%
160
1509
61
693
119
1043
102
1159
32
221
189
1981
15
11
206
2191
71
206
150
1995
133
1054
84
1130
147
1353
34
484
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
—
1.4e+00
—
—
—
3.1e+00
1.6e+00
—
—
cases:4.07%
controls:1.00%
—
—
—
—
—
—
cases:12.90%
controls:0.64%
cases:7.73%
controls:1.74%
—
9
22
212
2180
—
—
—
28
14
189
2170
14
32
167
1805
General Surgery
2 [38004447]
2 [38004447]
6.5e-01
6.2e-01
9.8e-01
—
3.3e+00
7.6e-01
6.6e-01
cases:24.43%
controls:14.44%
cases:8.60%
controls:4.81%
cases:2.26%
controls:0.86%
—
—
cases:17.65%
controls:0.77%
cases:8.29%
controls:4.08%
cases:21.55%
controls:12.47%
54
318
167
1884
19
106
202
2096
5
19
216
2183
—
39
17
182
2184
18
89
199
2095
39
229
142
1608
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1920-8 [3013721]
3.4e-01
1.4e+00
—
—
2.0e+00
5.4e-01
9.9e-01
cases:9.95%
controls:7.27%
cases:9.95%
controls:2.63%
—
—
—
—
cases:2.71%
controls:0.36%
cases:5.07%
controls:3.02%
cases:16.02%
controls:6.64%
22
160
199
2042
22
58
199
2144
—
—
6
8
215
2193
11
66
206
2118
29
122
152
1715
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
6.2e-01
1.5e+00
2.7e+00
1.0e+50
—
1.1e+00
7.3e-01
cases:8.14%
controls:4.54%
cases:4.07%
controls:0.91%
cases:3.17%
controls:0.23%
cases:2.26%
controls:0.00%
—
—
cases:4.61%
controls:1.60%
cases:9.39%
controls:4.74%
18
100
203
2102
9
20
212
2182
7
5
214
2197
5
0
216
2202
—
10
35
207
2149
17
87
164
1750
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
F10.1 [45595844]
2.0e+00
2.0e+00
—
—
—
2.0e+00
—
cases:4.52%
controls:0.64%
cases:2.26%
controls:0.32%
—
—
—
—
—
—
cases:2.76%
controls:0.37%
—
—
10
14
211
2188
5
7
216
2195
—
—
—
6
8
211
2176
—
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
N05BA01 [21604566]
1.2e+00
1.4e+00
—
—
—
—
1.4e+00
cases:8.14%
controls:2.72%
cases:4.98%
controls:1.23%
—
—
—
—
—
—
—
—
cases:7.18%
controls:1.80%
18
60
203
2142
11
27
210
2175
—
—
—
—
13
33
168
1804
Inpatient Visit
IP [9201]
IP [9201]
1.7e-01
1.1e+00
—
—
2.7e+00
1.3e+00
5.9e-01
cases:6.79%
controls:5.81%
cases:5.43%
controls:1.82%
—
—
—
—
cases:3.17%
controls:0.23%
cases:8.29%
controls:2.43%
cases:11.05%
controls:6.42%
15
128
206
2074
12
40
209
2162
—
—
7
5
214
2196
18
53
199
2131
20
118
161
1719
Exposure to unspecified factor
X59 [45756412]
X59 [45756412]
8.6e-02
2.1e+00
—
1.0e+50
—
1.5e+00
1.2e+00
cases:2.71%
controls:2.50%
cases:3.17%
controls:0.41%
—
—
cases:15.38%
controls:0.00%
—
—
cases:3.23%
controls:0.73%
cases:7.18%
controls:2.34%
6
55
215
2147
7
9
214
2193
—
34
0
187
2202
—
7
16
210
2168
13
43
168
1794
Bacteria identified in Urine by Culture
630-4 [3026008]
630-4 [3026008]
5.0e-01
1.2e+00
2.0e+00
—
—
5.2e-01
6.0e-01
cases:8.14%
controls:5.09%
cases:8.14%
controls:2.63%
cases:2.71%
controls:0.36%
—
—
—
—
cases:4.61%
controls:2.79%
cases:11.60%
controls:6.75%
18
112
203
2090
18
58
203
2144
6
8
215
2194
—
—
10
61
207
2123
21
124
160
1713
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
M01AE01 [21603967]
3.0e-01
3.5e-01
1.2e+00
—
2.0e+00
4.8e-01
3.9e-01
cases:40.72%
controls:33.74%
cases:20.36%
controls:15.21%
cases:5.88%
controls:1.91%
—
—
cases:12.22%
controls:1.82%
cases:22.12%
controls:14.97%
cases:44.75%
controls:35.44%
90
743
131
1459
45
335
176
1867
13
42
208
2160
—
27
40
194
2161
48
327
169
1857
81
651
100
1186
ibuprofen
R02AX02 [1588667]
R02AX02 [1588667]
3.0e-01
3.5e-01
1.2e+00
—
2.0e+00
4.8e-01
3.9e-01
cases:40.72%
controls:33.74%
cases:20.36%
controls:15.21%
cases:5.88%
controls:1.91%
—
—
cases:12.22%
controls:1.82%
cases:22.12%
controls:14.97%
cases:44.75%
controls:35.44%
90
743
131
1459
45
335
176
1867
13
42
208
2160
—
27
40
194
2161
48
327
169
1857
81
651
100
1186
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
2.2e-01
4.5e-01
1.3e+00
—
1.8e+00
4.8e-01
2.8e-01
cases:32.58%
controls:27.88%
cases:23.08%
controls:16.08%
cases:9.50%
controls:2.82%
—
—
cases:17.19%
controls:3.36%
cases:24.88%
controls:17.08%
cases:43.09%
controls:36.47%
72
614
149
1588
51
354
170
1848
21
62
200
2140
—
38
74
183
2127
54
373
163
1811
78
670
103
1167
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
N02AX02 [21604298]
6.2e-01
3.3e-01
1.4e+00
—
2.2e+00
1.7e-01
8.8e-01
cases:12.22%
controls:6.99%
cases:4.07%
controls:2.95%
cases:2.26%
controls:0.54%
—
—
cases:4.98%
controls:0.59%
cases:3.23%
controls:2.75%
cases:14.36%
controls:6.48%
27
154
194
2048
9
65
212
2137
5
12
216
2190
—
11
13
210
2188
7
60
210
2124
26
119
155
1718
Outpatient Hospital
22 [8756]
22 [8756]
4.8e-01
4.4e-01
1.5e+00
1.0e+50
2.2e+00
4.6e-01
7.7e-01
cases:31.22%
controls:21.98%
cases:8.60%
controls:5.72%
cases:2.71%
controls:0.59%
cases:4.07%
controls:0.00%
cases:7.24%
controls:0.86%
cases:7.83%
controls:5.08%
cases:25.97%
controls:13.94%
69
484
152
1718
19
126
202
2076
6
13
215
2189
9
0
212
2202
16
19
205
2182
17
111
200
2073
47
256
134
1581
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
1.3e+00
4.9e-01
3.4e-01
1.9e+00
9.4e-01
5.4e-01
1.7e+00
cases:98.19%
controls:93.37%
cases:87.33%
controls:80.93%
cases:51.13%
controls:42.60%
cases:13.12%
controls:2.27%
cases:64.71%
controls:41.75%
cases:88.48%
controls:81.73%
cases:98.90%
controls:94.12%
217
2056
4
146
193
1782
28
420
113
938
108
1264
29
50
192
2152
143
919
78
1282
192
1785
25
399
179
1729
2
108
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
2324-2 [3026910]
2.9e-01
8.0e-01
1.2e+00
—
2.0e+00
-8.8e-02
5.2e-01
cases:17.19%
controls:13.44%
cases:11.31%
controls:5.40%
cases:2.26%
controls:0.73%
—
—
cases:4.07%
controls:0.59%
cases:6.45%
controls:7.01%
cases:27.07%
controls:18.02%
38
296
183
1906
25
119
196
2083
5
16
216
2186
—
9
13
212
2188
14
153
203
2031
49
331
132
1506
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
1.8e-01
7.9e-01
1.2e+00
—
1.2e+00
4.1e-01
6.9e-01
cases:19.91%
controls:17.17%
cases:16.74%
controls:8.36%
cases:4.98%
controls:1.59%
—
—
cases:5.88%
controls:1.77%
cases:14.75%
controls:10.26%
cases:34.25%
controls:20.79%
44
378
177
1824
37
184
184
2018
11
35
210
2167
—
13
39
208
2162
32
224
185
1960
62
382
119
1455
pregabalin; oral
N02BF02 [955152]
N02BF02 [955152]
9.0e-01
9.0e-01
1.4e+00
—
—
1.5e+00
1.1e+00
cases:7.69%
controls:3.27%
cases:3.62%
controls:1.50%
cases:2.26%
controls:0.54%
—
—
—
—
cases:5.53%
controls:1.33%
cases:9.39%
controls:3.21%
17
72
204
2130
8
33
213
2169
5
12
216
2190
—
—
12
29
205
2155
17
59
164
1778
gabapentin; oral
N02BF01 [955005]
N02BF01 [955005]
4.5e-01
5.7e-01
—
—
—
1.3e+00
1.3e+00
cases:3.17%
controls:2.04%
cases:3.17%
controls:1.82%
—
—
—
—
—
—
cases:5.53%
controls:1.56%
cases:8.29%
controls:2.50%
7
45
214
2157
7
40
214
2162
—
—
—
12
34
205
2150
15
46
166
1791
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
1.3e-01
2.8e-01
1.1e+00
—
1.5e+00
2.9e-01
3.2e-01
cases:26.70%
controls:24.21%
cases:23.53%
controls:18.80%
cases:10.41%
controls:3.86%
—
—
cases:16.74%
controls:4.32%
cases:23.50%
controls:18.64%
cases:40.33%
controls:32.83%
59
533
162
1669
52
414
169
1788
23
85
198
2117
—
37
95
184
2106
51
407
166
1777
73
603
108
1234
Chest symptom/complaint
L04 [2002000629]
L04 [2002000629]
—
—
—
—
—
-1.0e+50
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:3.31%
controls:0.27%
—
—
—
—
—
0
6
217
2178
6
5
175
1832
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
7.5e-02
3.3e-01
1.1e+00
—
1.4e+00
3.6e-01
2.6e-01
cases:30.32%
controls:28.75%
cases:26.70%
controls:20.75%
cases:11.31%
controls:4.09%
—
—
cases:15.38%
controls:4.36%
cases:29.03%
controls:22.25%
cases:46.41%
controls:40.07%
67
633
154
1569
59
457
162
1745
25
90
196
2112
—
34
96
187
2105
63
486
154
1698
84
736
97
1101
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
890-4 [3001079]
2.9e-01
1.6e-01
—
—
2.5e+00
9.2e-01
5.7e-01
cases:11.31%
controls:8.72%
cases:4.07%
controls:3.50%
—
—
—
—
cases:3.62%
controls:0.32%
cases:7.37%
controls:3.07%
cases:14.92%
controls:8.98%
25
192
196
2010
9
77
212
2125
—
—
8
7
213
2194
16
67
201
2117
27
165
154
1672
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
2.2e-01
3.7e-01
1.0e+00
—
1.4e+00
3.6e-01
4.6e-01
cases:25.79%
controls:21.75%
cases:23.08%
controls:17.12%
cases:9.05%
controls:3.41%
—
—
cases:13.57%
controls:3.73%
cases:24.88%
controls:18.82%
cases:42.54%
controls:31.90%
57
479
164
1723
51
377
170
1825
20
75
201
2127
—
30
82
191
2119
54
411
163
1773
77
586
104
1251
Laceration/cut
S18 [2002000983]
S18 [2002000983]
4.8e-01
5.3e-01
—
—
2.4e+00
9.2e-01
4.0e-01
cases:10.41%
controls:6.72%
cases:4.52%
controls:2.72%
—
—
—
—
cases:4.98%
controls:0.45%
cases:5.53%
controls:2.29%
cases:12.15%
controls:8.49%
23
148
198
2054
10
60
211
2142
—
—
11
10
210
2191
12
50
205
2134
22
156
159
1681
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
9.2e-02
3.1e-01
1.1e+00
—
1.4e+00
3.3e-01
2.3e-01
cases:30.77%
controls:28.84%
cases:26.70%
controls:21.03%
cases:11.31%
controls:4.13%
—
—
cases:15.38%
controls:4.50%
cases:29.03%
controls:22.66%
cases:45.86%
controls:40.12%
68
635
153
1567
59
463
162
1739
25
91
196
2111
—
34
99
187
2102
63
495
154
1689
83
737
98
1100
Orthopedic Surgery
20 [38004465]
20 [38004465]
6.5e-01
9.8e-01
—
—
1.6e+00
5.0e-01
7.1e-01
cases:20.81%
controls:12.03%
cases:10.86%
controls:4.36%
—
—
—
—
cases:2.26%
controls:0.45%
cases:7.37%
controls:4.62%
cases:24.86%
controls:13.94%
46
265
175
1937
24
96
197
2106
—
—
5
10
216
2191
16
101
201
2083
45
256
136
1581
alprostadil; parenteral
C01EA01 [21600362]
C01EA01 [21600362]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.27%
—
—
—
—
—
—
5
5
176
1832
Assessment of need for oral health care, extensive
SAD02 [2001310288]
SAD02 [2001310288]
2.3e+00
-1.0e+50
—
—
—
—
—
cases:3.17%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
7
7
214
2195
0
5
221
2197
—
—
—
—
—
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.2e-01
3.5e-01
1.0e+00
—
1.3e+00
3.1e-01
3.5e-01
cases:33.94%
controls:31.38%
cases:31.22%
controls:24.25%
cases:12.22%
controls:4.81%
—
—
cases:17.19%
controls:5.32%
cases:32.72%
controls:26.37%
cases:52.49%
controls:43.66%
75
691
146
1511
69
534
152
1668
27
106
194
2096
—
38
117
183
2084
71
576
146
1608
95
802
86
1035
lidocaine; ointment
D04AB01 [21602020]
D04AB01 [21602020]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.44%
—
—
—
—
—
—
7
8
174
1829
lidocaine
C05AD01 [21601618]
C05AD01 [21601618]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.44%
—
—
—
—
—
—
7
8
174
1829
Pain in thoracic spine
M54.6 [45606247]
M54.6 [45606247]
2.2e+00
—
—
—
—
—
—
cases:3.62%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
8
9
213
2193
—
—
—
—
—
—
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
2.2e-01
6.9e-01
5.7e-01
—
1.4e+00
7.4e-01
5.2e-01
cases:14.48%
controls:11.99%
cases:12.22%
controls:6.54%
cases:3.17%
controls:1.82%
—
—
cases:7.69%
controls:1.95%
cases:12.90%
controls:6.59%
cases:21.55%
controls:13.99%
32
264
189
1938
27
144
194
2058
7
40
214
2162
—
17
43
204
2158
28
144
189
2040
39
257
142
1580
oxazepam; oral
N05BA04 [21604569]
N05BA04 [21604569]
9.1e-01
1.2e+00
—
—
1.7e+00
8.2e-01
8.3e-01
cases:9.95%
controls:4.27%
cases:7.24%
controls:2.23%
—
—
—
—
cases:2.71%
controls:0.50%
cases:5.07%
controls:2.29%
cases:10.50%
controls:4.84%
22
94
199
2108
16
49
205
2153
—
—
6
11
215
2190
11
50
206
2134
19
89
162
1748
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
4.9e-01
4.9e-01
1.2e+00
—
2.1e+00
8.4e-01
3.5e-01
cases:19.91%
controls:13.17%
cases:8.60%
controls:5.45%
cases:2.71%
controls:0.86%
—
—
cases:5.43%
controls:0.68%
cases:9.68%
controls:4.44%
cases:16.57%
controls:12.30%
44
290
177
1912
19
120
202
2082
6
19
215
2183
—
12
15
209
2186
21
97
196
2087
30
226
151
1611
disulfiram; oral
N07BB01 [21604821]
N07BB01 [21604821]
2.1e+00
—
—
—
—
—
2.2e+00
cases:3.17%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.33%
7
9
214
2193
—
—
—
—
—
5
6
176
1831
Psychological sympt/compl other
P29 [2002000823]
P29 [2002000823]
1.6e+00
2.0e+00
—
—
—
—
1.2e+00
cases:3.62%
controls:0.77%
cases:2.71%
controls:0.36%
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.25%
8
17
213
2185
6
8
215
2194
—
—
—
—
7
23
174
1814
Otolaryngology
4 [38004449]
4 [38004449]
1.3e-01
3.7e-01
—
—
2.0e+00
6.3e-01
4.3e-01
cases:11.31%
controls:10.08%
cases:4.52%
controls:3.18%
—
—
—
—
cases:2.71%
controls:0.36%
cases:5.53%
controls:3.02%
cases:13.81%
controls:9.42%
25
222
196
1980
10
70
211
2132
—
—
6
8
215
2193
12
66
205
2118
25
173
156
1664
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
2.7e-01
2.7e-01
5.7e-01
—
1.5e+00
3.4e-01
5.5e-01
cases:38.46%
controls:32.38%
cases:20.81%
controls:16.76%
cases:5.43%
controls:3.13%
—
—
cases:13.12%
controls:3.41%
cases:22.12%
controls:16.85%
cases:49.17%
controls:35.93%
85
713
136
1489
46
369
175
1833
12
69
209
2133
—
29
75
192
2126
48
368
169
1816
89
660
92
1177
boric acid
S02AA03 [21605149]
S02AA03 [21605149]
-1.0e+50
—
—
—
—
—
2.0e+00
cases:0.00%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.54%
0
21
221
2181
—
—
—
—
—
7
10
174
1827
vortioxetine; oral
N06AX26 [44819158]
N06AX26 [44819158]
2.0e+00
1.3e+00
—
—
—
1.5e+00
8.1e-01
cases:3.17%
controls:0.45%
cases:2.26%
controls:0.64%
—
—
—
—
—
—
cases:2.30%
controls:0.55%
cases:2.76%
controls:1.25%
7
10
214
2192
5
14
216
2188
—
—
—
5
12
212
2172
5
23
176
1814
pH of Urine by Test strip
5803-2 [3022621]
5803-2 [3022621]
—
2.0e+00
—
—
—
—
—
—
—
cases:3.17%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
7
10
214
2192
—
—
—
—
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
5894-1 [3033658]
3.2e-01
9.9e-01
—
1.0e+50
2.0e+00
5.5e-01
8.4e-01
cases:7.24%
controls:5.36%
cases:6.33%
controls:2.45%
—
—
cases:2.71%
controls:0.00%
cases:3.17%
controls:0.45%
cases:3.69%
controls:2.15%
cases:9.39%
controls:4.30%
16
118
205
2084
14
54
207
2148
—
6
0
215
2202
7
10
214
2191
8
47
209
2137
17
79
164
1758
Essential (primary) hypertension
I10 [45591453]
I10 [45591453]
2.6e-01
5.0e-01
1.0e+00
—
1.9e+00
3.0e-01
1.7e-01
cases:17.65%
controls:14.12%
cases:10.86%
controls:6.90%
cases:3.62%
controls:1.32%
—
—
cases:6.79%
controls:1.04%
cases:10.60%
controls:8.06%
cases:20.44%
controls:17.86%
39
311
182
1891
24
152
197
2050
8
29
213
2173
—
15
23
206
2178
23
176
194
2008
37
328
144
1509
Foot and toes X-ray examination
NH3AA [2001308267]
NH3AA [2001308267]
1.9e+00
—
—
—
—
—
—
cases:3.62%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
8
12
213
2190
—
—
—
—
—
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
2.0e-01
9.6e-03
1.9e+00
—
—
-3.5e-02
2.9e-01
cases:12.22%
controls:10.26%
cases:7.24%
controls:7.18%
cases:3.62%
controls:0.54%
—
—
—
—
cases:6.91%
controls:7.14%
cases:18.78%
controls:14.75%
27
226
194
1976
16
158
205
2044
8
12
213
2190
—
—
15
156
202
2028
34
271
147
1566
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
7.7e-01
—
—
—
—
-1.0e+50
1.9e+00
cases:4.98%
controls:2.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.46%
cases:3.87%
controls:0.60%
11
52
210
2150
—
—
—
—
0
10
217
2174
7
11
174
1826
Sleep apnoea
G47.3 [45562094]
G47.3 [45562094]
6.8e-01
7.2e-01
—
—
1.9e+00
5.2e-01
6.6e-01
cases:8.14%
controls:4.31%
cases:4.98%
controls:2.50%
—
—
—
—
cases:3.17%
controls:0.50%
cases:5.07%
controls:3.07%
cases:9.94%
controls:5.39%
18
95
203
2107
11
55
210
2147
—
—
7
11
214
2190
11
67
206
2117
18
99
163
1738
Immunohistochemistry procedure
117617002 [4035726]
117617002 [4035726]
9.0e-01
-1.0e+50
—
—
—
—
1.8e+00
cases:3.17%
controls:1.32%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.65%
7
29
214
2173
0
12
221
2190
—
—
—
—
7
12
174
1825
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
E11.8 [45561951]
1.0e+00
1.4e+00
—
—
—
1.8e+00
5.0e-01
cases:3.17%
controls:1.18%
cases:2.26%
controls:0.54%
—
—
—
—
—
—
cases:3.23%
controls:0.55%
cases:2.76%
controls:1.69%
7
26
214
2176
5
12
216
2190
—
—
—
7
12
210
2172
5
31
176
1806
Anxiety disorder, unspecified
F41.9 [45542849]
F41.9 [45542849]
1.3e+00
1.8e+00
-1.0e+50
—
—
—
9.9e-01
cases:3.17%
controls:0.91%
cases:3.62%
controls:0.64%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:3.87%
controls:1.47%
7
20
214
2182
8
14
213
2188
0
5
221
2197
—
—
—
7
27
174
1810
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
OMOP4821991 [45756751]
1.8e+00
—
—
—
—
—
—
cases:3.62%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
8
14
213
2188
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
4.0e-01
1.7e+00
—
—
—
—
1.3e+00
cases:4.07%
controls:2.77%
cases:3.62%
controls:0.68%
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.52%
9
61
212
2141
8
15
213
2187
—
—
—
—
10
28
171
1809
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.7e-01
3.0e-01
1.7e+00
—
9.8e-01
5.6e-01
5.2e-01
cases:14.48%
controls:12.49%
cases:6.79%
controls:5.13%
cases:3.62%
controls:0.68%
—
—
cases:2.26%
controls:0.86%
cases:8.76%
controls:5.22%
cases:20.99%
controls:13.66%
32
275
189
1927
15
113
206
2089
8
15
213
2187
—
5
19
216
2182
19
114
198
2070
38
251
143
1586
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
G03CA03 [21602517]
5.9e-01
8.5e-01
5.5e-01
—
—
8.4e-01
5.0e-01
cases:11.31%
controls:6.63%
cases:10.41%
controls:4.72%
cases:2.26%
controls:1.32%
—
—
—
—
cases:11.06%
controls:5.08%
cases:13.81%
controls:8.82%
25
146
196
2056
23
104
198
2098
5
29
216
2173
—
—
24
111
193
2073
25
162
156
1675
olanzapine; oral, parenteral
N05AH03 [21604543]
N05AH03 [21604543]
1.4e+00
—
—
—
—
—
1.7e+00
cases:3.62%
controls:0.95%
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.09%
8
21
213
2181
—
—
—
—
—
10
20
171
1817
Bacteria identified in Isolate by Culture
43409-2 [3042936]
43409-2 [3042936]
5.2e-01
—
—
—
—
1.6e+00
8.4e-01
cases:3.62%
controls:2.18%
—
—
—
—
—
—
—
—
cases:3.69%
controls:0.73%
cases:5.52%
controls:2.45%
8
48
213
2154
—
—
—
—
8
16
209
2168
10
45
171
1792
Mixed anxiety and depressive disorder
F41.2 [45566845]
F41.2 [45566845]
1.6e+00
—
—
—
—
1.3e+00
1.4e+00
cases:4.07%
controls:0.82%
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.73%
cases:5.52%
controls:1.47%
9
18
212
2184
—
—
—
—
6
16
211
2168
10
27
171
1810
Exposure to other specified factors
X58 [45756411]
X58 [45756411]
1.6e+00
—
—
1.0e+50
—
—
1.3e+00
cases:6.79%
controls:1.41%
—
—
—
—
cases:6.79%
controls:0.00%
—
—
—
—
cases:5.52%
controls:1.63%
15
31
206
2171
—
—
15
0
206
2202
—
—
10
30
171
1807
ranitidine bismuth citrate; oral
A02BA07 [21600088]
A02BA07 [21600088]
1.6e+00
2.3e+00
—
—
—
—
1.5e+00
cases:4.98%
controls:1.09%
cases:2.26%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.76%
11
24
210
2178
5
5
216
2197
—
—
—
—
6
14
175
1823
ranitidine; oral, parenteral
A02BA02 [21600083]
A02BA02 [21600083]
1.6e+00
2.3e+00
—
—
—
—
1.5e+00
cases:4.98%
controls:1.09%
cases:2.26%
controls:0.23%
—
—
—
—
—
—
—
—
cases:3.31%
controls:0.76%
11
24
210
2178
5
5
216
2197
—
—
—
—
6
14
175
1823
hydroxyzine; oral, parenteral
N05BB01 [21604590]
N05BB01 [21604590]
1.1e+00
—
-1.0e+50
—
—
1.3e+00
1.5e+00
cases:4.98%
controls:1.77%
—
—
cases:0.00%
controls:0.23%
—
—
—
—
cases:2.76%
controls:0.73%
cases:6.08%
controls:1.36%
11
39
210
2163
—
0
5
221
2197
—
—
6
16
211
2168
11
25
170
1812
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
7.4e-01
—
—
—
—
—
1.5e+00
cases:2.26%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:4.97%
controls:1.14%
5
24
216
2178
—
—
—
—
—
9
21
172
1816
Internal Medicine
11 [38004456]
11 [38004456]
2.9e-01
4.1e-01
7.1e-01
—
9.0e-01
7.9e-01
7.1e-01
cases:23.98%
controls:19.03%
cases:11.31%
controls:7.81%
cases:3.17%
controls:1.59%
—
—
cases:3.62%
controls:1.50%
cases:14.29%
controls:7.01%
cases:28.18%
controls:16.11%
53
419
168
1783
25
172
196
2030
7
35
214
2167
—
8
33
213
2168
31
153
186
2031
51
296
130
1541
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
5.4e-01
6.0e-01
—
—
—
1.4e+00
5.8e-01
cases:8.60%
controls:5.18%
cases:3.17%
controls:1.77%
—
—
—
—
—
—
cases:5.53%
controls:1.47%
cases:11.05%
controls:6.48%
19
114
202
2088
7
39
214
2163
—
—
—
12
32
205
2152
20
119
161
1718
duloxetine; oral
N06AX21 [21604749]
N06AX21 [21604749]
1.3e+00
—
—
—
—
—
9.9e-01
cases:5.43%
controls:1.50%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.47%
12
33
209
2169
—
—
—
—
—
7
27
174
1810
CBC panel - Blood by Automated count
58410-2 [40761511]
58410-2 [40761511]
-3.7e-02
1.5e-01
9.0e-01
—
1.3e+00
3.1e-01
1.7e-01
cases:29.86%
controls:30.65%
cases:21.72%
controls:19.30%
cases:7.24%
controls:3.09%
—
—
cases:11.76%
controls:3.45%
cases:23.96%
controls:18.73%
cases:41.99%
controls:38.00%
66
675
155
1527
48
425
173
1777
16
68
205
2134
—
26
76
195
2125
52
409
165
1775
76
698
105
1139
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
4.7e-01
—
—
—
—
1.3e+00
7.4e-01
cases:12.22%
controls:7.99%
—
—
—
—
—
—
—
—
cases:6.45%
controls:1.92%
cases:11.05%
controls:5.61%
27
176
194
2026
—
—
—
—
14
42
203
2142
20
103
161
1734
Dentistry
C5 [903277]
C5 [903277]
3.6e-01
—
—
—
—
1.3e+00
1.2e+00
cases:3.62%
controls:2.54%
—
—
—
—
—
—
—
—
cases:3.23%
controls:0.92%
cases:7.18%
controls:2.18%
8
56
213
2146
—
—
—
—
7
20
210
2164
13
40
168
1797
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
14732-2 [3021960]
1.4e-02
—
—
—
—
1.2e+00
4.9e-01
cases:2.71%
controls:2.68%
—
—
—
—
—
—
—
—
cases:7.83%
controls:2.43%
cases:9.94%
controls:6.31%
6
59
215
2143
—
—
—
—
17
53
200
2131
18
116
163
1721
temazepam; oral
N05CD07 [21604642]
N05CD07 [21604642]
8.5e-01
6.1e-01
—
—
—
1.1e+00
1.2e+00
cases:6.33%
controls:2.82%
cases:2.71%
controls:1.50%
—
—
—
—
—
—
cases:3.69%
controls:1.24%
cases:7.73%
controls:2.40%
14
62
207
2140
6
33
215
2169
—
—
—
8
27
209
2157
14
44
167
1793
Pain in limb
M79.6 [45587063]
M79.6 [45587063]
6.6e-01
4.6e-01
-1.0e+50
—
—
1.2e+00
3.2e-01
cases:9.50%
controls:5.13%
cases:3.62%
controls:2.32%
cases:0.00%
controls:0.23%
—
—
—
—
cases:6.91%
controls:2.15%
cases:11.05%
controls:8.27%
21
113
200
2089
8
51
213
2151
0
5
221
2197
—
—
15
47
202
2137
20
152
161
1685
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
1.2e+00
1.5e+00
—
—
—
1.5e+00
2.8e-01
cases:5.88%
controls:1.86%
cases:2.71%
controls:0.64%
—
—
—
—
—
—
cases:2.30%
controls:0.55%
cases:3.87%
controls:2.94%
13
41
208
2161
6
14
215
2188
—
—
—
5
12
212
2172
7
54
174
1783
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
2.8e-01
3.3e-01
8.0e-01
—
1.2e+00
5.5e-01
4.7e-01
cases:12.67%
controls:9.90%
cases:9.05%
controls:6.68%
cases:3.17%
controls:1.45%
—
—
cases:5.88%
controls:1.91%
cases:12.44%
controls:7.60%
cases:17.68%
controls:11.87%
28
218
193
1984
20
147
201
2055
7
32
214
2170
—
13
42
208
2159
27
166
190
2018
32
218
149
1619
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
1.3e-01
4.7e-01
7.4e-01
—
1.2e+00
2.6e-01
3.0e-01
cases:32.58%
controls:29.88%
cases:29.86%
controls:21.07%
cases:7.24%
controls:3.59%
—
—
cases:10.86%
controls:3.68%
cases:27.19%
controls:22.30%
cases:49.72%
controls:42.24%
72
658
149
1544
66
464
155
1738
16
79
205
2123
—
24
81
197
2120
59
487
158
1697
90
776
91
1061
propranolol; oral, parenteral
C07AA05 [21601670]
C07AA05 [21601670]
5.2e-01
1.1e+00
—
—
—
1.2e+00
7.0e-01
cases:5.88%
controls:3.59%
cases:5.43%
controls:1.86%
—
—
—
—
—
—
cases:5.99%
controls:1.97%
cases:8.29%
controls:4.30%
13
79
208
2123
12
41
209
2161
—
—
—
13
43
204
2141
15
79
166
1758
Tissue Pathology biopsy report
66121-5 [40768804]
66121-5 [40768804]
3.0e-01
—
-1.0e+50
—
—
1.1e+00
4.1e-01
cases:8.14%
controls:6.18%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
cases:5.99%
controls:2.01%
cases:8.29%
controls:5.66%
18
136
203
2066
—
0
7
221
2195
—
—
13
44
204
2140
15
104
166
1733
clarithromycin; oral, parenteral
J01FA09 [21602977]
J01FA09 [21602977]
7.9e-01
1.2e+00
—
—
—
—
1.1e+00
cases:4.98%
controls:2.32%
cases:2.71%
controls:0.82%
—
—
—
—
—
—
—
—
cases:8.84%
controls:3.05%
11
51
210
2151
6
18
215
2184
—
—
—
—
16
56
165
1781
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
14933-6 [3026493]
3.9e-01
1.1e+00
-1.0e+50
—
—
6.2e-01
3.0e-01
cases:8.14%
controls:5.68%
cases:6.79%
controls:2.32%
cases:0.00%
controls:0.23%
—
—
—
—
cases:3.69%
controls:2.01%
cases:8.29%
controls:6.26%
18
125
203
2077
15
51
206
2151
0
5
221
2197
—
—
8
44
209
2140
15
115
166
1722
quetiapine; oral
N05AH04 [21604544]
N05AH04 [21604544]
1.1e+00
1.1e+00
—
—
—
8.2e-01
7.3e-01
cases:7.69%
controls:2.68%
cases:5.43%
controls:1.91%
—
—
—
—
—
—
cases:5.07%
controls:2.29%
cases:7.73%
controls:3.86%
17
59
204
2143
12
42
209
2160
—
—
—
11
50
206
2134
14
71
167
1766
Low back symptom/complaint
L03 [2002000628]
L03 [2002000628]
1.1e+00
—
—
—
—
1.3e+00
7.3e-01
cases:7.69%
controls:2.77%
—
—
—
—
—
—
—
—
cases:3.69%
controls:1.01%
cases:8.29%
controls:4.19%
17
61
204
2141
—
—
—
—
8
22
209
2162
15
77
166
1760
mirtazapine; oral
N06AX11 [21604740]
N06AX11 [21604740]
6.4e-01
7.7e-01
8.3e-01
—
1.5e+00
1.1e+00
5.8e-01
cases:10.86%
controls:6.04%
cases:6.79%
controls:3.27%
cases:2.26%
controls:1.00%
—
—
cases:3.17%
controls:0.73%
cases:7.83%
controls:2.88%
cases:11.60%
controls:6.86%
24
133
197
2069
15
72
206
2130
5
22
216
2180
—
7
16
214
2185
17
63
200
2121
21
126
160
1711
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
6.8e-01
1.0e+00
—
—
—
5.5e-01
1.0e+00
cases:5.43%
controls:2.82%
cases:3.62%
controls:1.32%
—
—
—
—
—
—
cases:3.23%
controls:1.88%
cases:8.84%
controls:3.38%
12
62
209
2140
8
29
213
2173
—
—
—
7
41
210
2143
16
62
165
1775
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
72160-5 [43054903]
8.0e-02
5.1e-01
—
—
—
1.0e+00
3.8e-01
cases:8.60%
controls:7.99%
cases:4.52%
controls:2.77%
—
—
—
—
—
—
cases:9.22%
controls:3.57%
cases:13.26%
controls:9.47%
19
176
202
2026
10
61
211
2141
—
—
—
20
78
197
2106
24
174
157
1663
Cough
R05 [2002000886]
R05 [2002000886]
7.0e-01
—
—
—
—
—
9.9e-01
cases:5.43%
controls:2.77%
—
—
—
—
—
—
—
—
—
—
cases:8.84%
controls:3.48%
12
61
209
2141
—
—
—
—
—
16
64
165
1773
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
9.8e-01
1.1e+00
—
—
—
—
6.3e-01
cases:10.86%
controls:4.36%
cases:2.71%
controls:0.95%
—
—
—
—
—
—
—
—
cases:4.97%
controls:2.72%
24
96
197
2106
6
21
215
2181
—
—
—
—
9
50
172
1787
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
3.2e-01
7.7e-01
—
—
—
—
9.8e-01
cases:4.52%
controls:3.32%
cases:2.71%
controls:1.27%
—
—
—
—
—
—
—
—
cases:9.39%
controls:3.76%
10
73
211
2129
6
28
215
2174
—
—
—
—
17
69
164
1768
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
1.3e-01
9.1e-01
1.1e+00
—
1.5e+00
7.4e-01
4.8e-01
cases:10.41%
controls:9.26%
cases:9.50%
controls:4.04%
cases:2.71%
controls:0.95%
—
—
cases:2.71%
controls:0.59%
cases:10.60%
controls:5.36%
cases:16.57%
controls:11.00%
23
204
198
1998
21
89
200
2113
6
21
215
2181
—
6
13
215
2188
23
117
194
2067
30
202
151
1635
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
EB1HA [2001301913]
-8.2e-02
—
—
—
-1.0e+50
2.1e-01
8.7e-01
cases:7.24%
controls:7.81%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:2.30%
controls:1.88%
cases:12.15%
controls:5.50%
16
172
205
2030
—
—
—
0
6
221
2195
5
41
212
2143
22
101
159
1736
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
2.0e-01
7.4e-01
—
—
1.3e+00
8.4e-01
4.8e-01
cases:9.95%
controls:8.27%
cases:8.14%
controls:4.04%
—
—
—
—
cases:2.71%
controls:0.77%
cases:11.52%
controls:5.31%
cases:18.23%
controls:12.08%
22
182
199
2020
18
89
203
2113
—
—
6
17
215
2184
25
116
192
2068
33
222
148
1615
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
5.9e-01
9.0e-01
—
—
—
7.8e-01
8.4e-01
cases:8.60%
controls:4.95%
cases:5.43%
controls:2.27%
—
—
—
—
—
—
cases:5.99%
controls:2.84%
cases:12.71%
controls:5.93%
19
109
202
2093
12
50
209
2152
—
—
—
13
62
204
2122
23
109
158
1728
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
6.7e-01
6.5e-01
—
—
1.4e+00
7.0e-01
8.3e-01
cases:11.76%
controls:6.40%
cases:6.33%
controls:3.41%
—
—
—
—
cases:4.07%
controls:1.04%
cases:8.29%
controls:4.30%
cases:14.92%
controls:7.08%
26
141
195
2061
14
75
207
2127
—
—
9
23
212
2178
18
94
199
2090
27
130
154
1707
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.6e-01
2.7e-01
—
—
-1.0e+50
5.5e-01
7.8e-01
cases:8.60%
controls:7.40%
cases:2.71%
controls:2.09%
—
—
—
—
cases:0.00%
controls:0.23%
cases:3.69%
controls:2.15%
cases:14.92%
controls:7.46%
19
163
202
2039
6
46
215
2156
—
—
0
5
221
2196
8
47
209
2137
27
137
154
1700
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
6.0e-01
8.5e-01
—
—
—
6.2e-01
7.8e-01
cases:9.95%
controls:5.72%
cases:6.33%
controls:2.82%
—
—
—
—
—
—
cases:6.45%
controls:3.57%
cases:14.92%
controls:7.46%
22
126
199
2076
14
62
207
2140
—
—
—
14
78
203
2106
27
137
154
1700
General health counselling
SPAT1312 [2001700413]
SPAT1312 [2001700413]
7.6e-01
9.5e-01
-1.0e+50
—
—
—
5.0e-01
cases:13.12%
controls:6.58%
cases:5.43%
controls:2.18%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:8.84%
controls:5.55%
29
145
192
2057
12
48
209
2154
0
6
221
2196
—
—
—
16
102
165
1735
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
4.7e-01
4.0e-01
—
—
8.3e-01
3.1e-01
7.0e-01
cases:19.00%
controls:12.81%
cases:11.31%
controls:7.86%
—
—
—
—
cases:3.17%
controls:1.41%
cases:11.06%
controls:8.33%
cases:29.28%
controls:17.09%
42
282
179
1920
25
173
196
2029
—
—
7
31
214
2170
24
182
193
2002
53
314
128
1523
Pulmonary Disease
29 [38004472]
29 [38004472]
6.8e-01
2.7e-01
—
—
—
4.5e-01
3.1e-01
cases:15.38%
controls:8.40%
cases:4.98%
controls:3.86%
—
—
—
—
—
—
cases:6.91%
controls:4.53%
cases:11.60%
controls:8.76%
34
185
187
2017
11
85
210
2117
—
—
—
15
99
202
2085
21
161
160
1676
tizanidine; oral
M03BX02 [21604116]
M03BX02 [21604116]
6.2e-01
6.1e-01
—
—
-1.0e+50
7.2e-01
4.9e-01
cases:21.27%
controls:12.72%
cases:6.79%
controls:3.81%
—
—
—
—
cases:0.00%
controls:0.73%
cases:8.29%
controls:4.21%
cases:17.13%
controls:11.27%
47
280
174
1922
15
84
206
2118
—
—
0
16
221
2185
18
92
199
2092
31
207
150
1630
varenicline; oral
N07BA03 [21604819]
N07BA03 [21604819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
221
2188
—
—
—
—
—
—
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
SFC01 [2001310369]
2.7e-01
7.7e-01
—
—
—
5.3e-01
1.3e-01
cases:4.98%
controls:3.86%
cases:2.71%
controls:1.27%
—
—
—
—
—
—
cases:2.76%
controls:1.65%
cases:4.97%
controls:4.41%
11
85
210
2117
6
28
215
2174
—
—
—
6
36
211
2148
9
81
172
1756
drospirenone and ethinylestradiol
G03AA12 [21602485]
G03AA12 [21602485]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
0
8
221
2193
—
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
72171-2 [43054914]
4.6e-01
—
—
—
—
-1.0e+50
—
cases:3.62%
controls:2.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
8
51
213
2151
—
—
—
—
0
13
217
2171
—
Extensive health check-up of expecting family
SPAT1197 [2001700298]
SPAT1197 [2001700298]
-3.7e-03
—
—
—
—
—
—
cases:2.26%
controls:2.27%
—
—
—
—
—
—
—
—
—
—
—
—
5
50
216
2152
—
—
—
—
—
—
hydroxocobalamin; parenteral
B03BA03 [21601123]
B03BA03 [21601123]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
—
—
—
0
19
181
1818
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
—
1.4e+00
—
—
—
1.6e+00
1.1e+00
—
—
cases:2.26%
controls:0.54%
—
—
—
—
—
—
cases:2.76%
controls:0.60%
cases:6.63%
controls:2.40%
—
5
12
216
2190
—
—
—
6
13
211
2171
12
44
169
1793
Atherosclerotic heart disease
I25.1 [45596196]
I25.1 [45596196]
4.4e-02
—
-1.0e+50
—
-1.0e+50
4.3e-01
1.5e-01
cases:4.07%
controls:3.91%
—
—
cases:0.00%
controls:0.23%
—
—
cases:0.00%
controls:0.32%
cases:3.69%
controls:2.43%
cases:5.52%
controls:4.79%
9
86
212
2116
—
0
5
221
2197
—
0
7
221
2194
8
53
209
2131
10
88
171
1749
Shoulder symptom/complaint
L08 [2002000632]
L08 [2002000632]
6.8e-01
—
—
—
—
—
9.2e-02
cases:3.62%
controls:1.86%
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:3.54%
8
41
213
2161
—
—
—
—
—
7
65
174
1772
Superficial injury of scalp
S00.0 [45548998]
S00.0 [45548998]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
181
1831
acetylsalicylic acid; oral
B01AC06 [21600991]
B01AC06 [21600991]
3.5e-01
—
—
—
—
—
—
cases:4.07%
controls:2.91%
—
—
—
—
—
—
—
—
—
—
—
—
9
64
212
2138
—
—
—
—
—
—
azelaic acid; ointment
D10AX03 [21602314]
D10AX03 [21602314]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.49%
0
18
221
2184
—
—
—
—
0
8
217
2176
0
9
181
1828
trimethoprim; oral, parenteral
J01EA01 [21602931]
J01EA01 [21602931]
4.6e-01
8.6e-01
—
—
—
—
4.6e-01
cases:6.79%
controls:4.41%
cases:3.17%
controls:1.36%
—
—
—
—
—
—
—
—
cases:7.73%
controls:5.01%
15
97
206
2105
7
30
214
2172
—
—
—
—
14
92
167
1745
Hallux valgus (acquired)
M20.1 [45606152]
M20.1 [45606152]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
217
2179
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
14771-0 [3018251]
2.7e-01
3.6e-01
4.4e-01
—
—
1.3e-01
2.9e-01
cases:29.86%
controls:24.57%
cases:18.55%
controls:13.71%
cases:2.71%
controls:1.77%
—
—
—
—
cases:16.59%
controls:14.84%
cases:41.99%
controls:35.11%
66
541
155
1661
41
302
180
1900
6
39
215
2163
—
—
36
324
181
1860
76
645
105
1192
Laparoscopic cholecystectomy
JKA21 [2001305294]
JKA21 [2001305294]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
0
7
221
2195
—
—
—
—
0
14
181
1823
Handing over of treatment supplies
SPAT1262 [2001700363]
SPAT1262 [2001700363]
4.1e-01
3.6e-01
-1.0e+50
—
—
-1.3e-01
5.5e-02
cases:5.88%
controls:4.00%
cases:3.17%
controls:2.23%
cases:0.00%
controls:0.32%
—
—
—
—
cases:2.30%
controls:2.61%
cases:4.42%
controls:4.19%
13
88
208
2114
7
49
214
2153
0
7
221
2195
—
—
5
57
212
2127
8
77
173
1760
diclofenac; ointment
M02AA15 [21604051]
M02AA15 [21604051]
6.2e-01
9.7e-01
—
—
—
—
6.5e-01
cases:3.17%
controls:1.73%
cases:2.71%
controls:1.04%
—
—
—
—
—
—
—
—
cases:4.97%
controls:2.67%
7
38
214
2164
6
23
215
2179
—
—
—
—
9
49
172
1788
Other abnormal findings on antenatal screening of mother
O28.8 [45548729]
O28.8 [45548729]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
clonazepam; oral, parenteral
N03AE01 [21604415]
N03AE01 [21604415]
—
—
—
—
—
1.5e+00
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:2.30%
controls:0.50%
cases:3.87%
controls:0.98%
—
—
—
—
—
5
11
212
2173
7
18
174
1819
flucloxacillin; oral, parenteral
J01CF05 [21602857]
J01CF05 [21602857]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
cefaclor; oral
J01DC04 [21602886]
J01DC04 [21602886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
221
2186
—
—
—
—
—
—
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2000-8 [3015377]
3.3e-01
—
—
—
—
2.1e-01
3.8e-01
cases:8.60%
controls:6.31%
—
—
—
—
—
—
—
—
cases:2.76%
controls:2.24%
cases:9.94%
controls:7.02%
19
139
202
2063
—
—
—
—
6
49
211
2135
18
129
163
1708
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
—
1.4e+00
—
—
—
1.5e+00
1.0e+00
—
—
cases:2.26%
controls:0.54%
—
—
—
—
—
—
cases:2.76%
controls:0.64%
cases:6.63%
controls:2.45%
—
5
12
216
2190
—
—
—
6
14
211
2170
12
45
169
1792
Dry eye syndrome
H04.10 [2000502254]
H04.10 [2000502254]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
15
221
2187
0
8
221
2194
—
—
—
—
—
Occupational health examination
Z10.0 [45581006]
Z10.0 [45581006]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
—
0
12
217
2172
—
Small restoration
SFA00 [2001310357]
SFA00 [2001310357]
—
—
—
—
—
—
5.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.58%
—
—
—
—
—
—
5
29
176
1808
clobazam; oral
N05BA09 [21604574]
N05BA09 [21604574]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Abdominal pain epigastric
D02 [2002000301]
D02 [2002000301]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
0
12
181
1825
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
32731-2 [3043747]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.87%
—
—
—
—
—
—
7
16
174
1821
Outcome of delivery
Z37 [45581024]
Z37 [45581024]
-1.8e-01
—
—
—
—
—
5.2e-01
cases:4.52%
controls:5.36%
—
—
—
—
—
—
—
—
—
—
cases:6.08%
controls:3.70%
10
118
211
2084
—
—
—
—
—
11
68
170
1769
codeine; oral
R05DA04 [21603399]
R05DA04 [21603399]
—
—
—
—
—
—
1.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:2.40%
—
—
—
—
—
—
5
44
176
1793
Blood and Immunity, Result test/procedure
B60 [2002000271]
B60 [2002000271]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
88518-6 [36304997]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
221
2194
—
—
—
—
—
—
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
1.7e-01
8.3e-01
1.1e+00
—
1.4e+00
7.5e-01
5.7e-01
cases:9.50%
controls:8.17%
cases:7.69%
controls:3.50%
cases:2.26%
controls:0.77%
—
—
cases:2.26%
controls:0.55%
cases:9.22%
controls:4.58%
cases:15.47%
controls:9.42%
21
180
200
2022
17
77
204
2125
5
17
216
2185
—
5
12
216
2189
20
100
197
2084
28
173
153
1664
Emergency visit or other similar visit involving procedures
WYA05 [2001310871]
WYA05 [2001310871]
-7.1e-02
-1.6e-01
—
—
—
—
2.2e-01
cases:8.60%
controls:9.17%
cases:2.26%
controls:2.63%
—
—
—
—
—
—
—
—
cases:9.39%
controls:7.68%
19
202
202
2000
5
58
216
2144
—
—
—
—
17
141
164
1696
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
DM1QA [2001301761]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
221
2193
—
—
—
—
—
—
Buprenorphine [Presence] in Urine by Screen method
93494-3 [1001926]
93494-3 [1001926]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.93%
—
—
—
—
—
—
7
17
174
1820
Pulp capping
SGC10 [2001310393]
SGC10 [2001310393]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.98%
—
0
6
221
2196
—
—
—
—
5
18
176
1819
Esophagoscopy, gastroscopy and duodenoscopy
SPAT1130 [2001700231]
SPAT1130 [2001700231]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
221
2194
—
—
—
—
—
—
Change in faeces/bowel movements
D18 [2002000317]
D18 [2002000317]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
Assessment of need for orthodontic treatment
SJF01 [2001310449]
SJF01 [2001310449]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Bordetella pertussis Ab [Titer] in Serum
22116-8 [3025018]
22116-8 [3025018]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Periodontitis UNS
K05.39 [2000502733]
K05.39 [2000502733]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
SPAT1380 [2001700480]
—
-1.0e+50
—
—
—
-1.0e+50
1.1e+00
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:2.76%
controls:0.98%
—
0
8
221
2194
—
—
—
0
13
217
2171
5
18
176
1819
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
14979-9 [3018677]
6.1e-01
—
—
—
—
—
1.2e+00
cases:6.33%
controls:3.54%
—
—
—
—
—
—
—
—
—
—
cases:6.63%
controls:2.12%
14
78
207
2124
—
—
—
—
—
12
39
169
1798
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
SMOKING-2-2-0 [2002330110]
-3.2e-01
—
—
—
—
—
—
cases:2.26%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
—
—
5
68
216
2134
—
—
—
—
—
—
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
ZXM10 [2001311446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
221
2190
—
—
—
—
—
—
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.82%
—
0
9
221
2193
—
—
—
—
7
15
174
1822
Heart failure
I50 [45581779]
I50 [45581779]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
221
2190
—
—
—
—
—
—
Atrial fibrillation/flutter
K78 [2002000605]
K78 [2002000605]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.69%
—
—
—
—
—
—
—
0
15
217
2169
—
Necrosis of pulp
K04.1 [45572186]
K04.1 [45572186]
7.0e-01
-1.0e+50
—
—
—
—
6.0e-01
cases:2.26%
controls:1.14%
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
cases:3.31%
controls:1.85%
5
25
216
2177
0
12
221
2190
—
—
—
—
6
34
175
1803
Unspecified privation
X57 [45756410]
X57 [45756410]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:2.26%
controls:0.00%
—
—
—
—
—
—
—
—
—
5
0
216
2202
—
—
—
Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum
16135-6 [3018658]
16135-6 [3018658]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Verruca simplex
B07.9 [2000500357]
B07.9 [2000500357]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
181
1831
Transurethral resection of prostate
KED22 [2001306138]
KED22 [2001306138]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2191
—
—
—
—
—
—
Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma
25373-2 [3019145]
25373-2 [3019145]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2191
—
—
—
—
—
Dog dander IgE Ab [Units/volume] in Serum
6098-8 [3014133]
6098-8 [3014133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
10
181
1827
Burn/scald
S14 [2002000979]
S14 [2002000979]
—
—
1.0e+50
1.0e+50
1.0e+50
—
-1.0e+50
—
—
—
—
cases:3.62%
controls:0.00%
cases:2.26%
controls:0.00%
cases:20.81%
controls:0.00%
—
—
cases:0.00%
controls:0.38%
—
—
8
0
213
2202
5
0
216
2202
46
0
175
2201
—
0
7
181
1830
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
WX602 [2001310813]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
gemfibrozil; oral
C10AB04 [21601868]
C10AB04 [21601868]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Paraesthesia of skin
R20.2 [45568120]
R20.2 [45568120]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
0
11
181
1826
denosumab; parenteral
M05BX04 [21604169]
M05BX04 [21604169]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.71%
0
6
221
2196
0
10
221
2192
—
—
—
0
11
217
2173
0
13
181
1824
Other investigative procedure of eye
XCW99 [2001301491]
XCW99 [2001301491]
6.4e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:2.71%
controls:1.45%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
6
32
215
2170
0
9
221
2193
—
—
—
0
8
217
2176
—
Shortness of breath/dyspnoea
R02 [2002000883]
R02 [2002000883]
—
1.2e+00
—
—
—
—
1.1e+00
—
—
cases:2.26%
controls:0.68%
—
—
—
—
—
—
—
—
cases:6.08%
controls:2.18%
—
5
15
216
2187
—
—
—
—
11
40
170
1797
Attendant Care Provider
3747A0650X [38004431]
3747A0650X [38004431]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
181
1831
Lumbar epidural anesthesia
WX306 [2001310796]
WX306 [2001310796]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
0
20
221
2182
—
—
—
—
—
0
11
181
1826
promethazine, combinations
R06AD52 [21603489]
R06AD52 [21603489]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
217
2179
—
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
51484-4 [3030981]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:1.63%
—
—
—
—
—
—
8
30
173
1807
Toothache NOS
K08.80 [2000502799]
K08.80 [2000502799]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
9
217
2175
—
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
3.8e-01
7.9e-01
1.2e+00
—
1.2e+00
7.0e-01
4.8e-01
cases:13.57%
controls:9.67%
cases:9.95%
controls:4.77%
cases:2.71%
controls:0.86%
—
—
cases:4.52%
controls:1.36%
cases:10.60%
controls:5.59%
cases:16.57%
controls:10.94%
30
213
191
1989
22
105
199
2097
6
19
215
2183
—
10
30
211
2171
23
122
194
2062
30
201
151
1636
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
R86.0 [45548987]
R86.0 [45548987]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
0
5
221
2197
—
—
—
—
—
Electrocardiogram with exercise test
46136006 [4261794]
46136006 [4261794]
8.8e-01
-1.0e+50
—
—
—
—
—
cases:2.26%
controls:0.95%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
5
21
216
2181
0
5
221
2197
—
—
—
—
—
Lower leg X-ray examination
NG4AA [2001308083]
NG4AA [2001308083]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
nystatin
D01AA01 [21601911]
D01AA01 [21601911]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
IgG subclass 4 [Mass/volume] in Serum
2469-5 [3024980]
2469-5 [3024980]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
zolmitriptan; nasal, oral
N02CC03 [21604378]
N02CC03 [21604378]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.49%
—
0
8
221
2194
—
—
—
0
6
217
2178
0
9
181
1828
Restricted health certificate
SPAT1283 [2001700384]
SPAT1283 [2001700384]
4.9e-01
1.1e+00
—
—
—
—
2.6e-01
cases:5.43%
controls:3.41%
cases:2.71%
controls:0.95%
—
—
—
—
—
—
—
—
cases:3.87%
controls:2.99%
12
75
209
2127
6
21
215
2181
—
—
—
—
7
55
174
1782
meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated
J07AH08 [21601303]
J07AH08 [21601303]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
Other minor procedure in surgery of teeth, jaws, mouth and pharynx
TEW99 [2001302349]
TEW99 [2001302349]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
221
2193
—
—
—
—
—
—
Phlebitis and thrombophlebitis of femoral vein
I80.1 [45543220]
I80.1 [45543220]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
181
1832
Pharmacological induction or advancement of labor
MAC40 [2001306872]
MAC40 [2001306872]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
181
1832
Health maint/preventive medicine
A98 [2002000231]
A98 [2002000231]
1.7e-01
-6.3e-02
6.9e-02
—
7.1e-01
7.7e-02
2.2e-01
cases:40.72%
controls:36.65%
cases:25.79%
controls:27.02%
cases:5.43%
controls:5.09%
—
—
cases:9.50%
controls:4.91%
cases:30.41%
controls:28.80%
cases:55.80%
controls:50.30%
90
807
131
1395
57
595
164
1607
12
112
209
2090
—
21
108
200
2093
66
629
151
1555
101
924
80
913
Removal wax from ear
TDA90 [2001301543]
TDA90 [2001301543]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
chlorhexidine, combinations
D08AC52 [21602208]
D08AC52 [21602208]
2.8e-01
—
—
—
—
—
—
cases:3.17%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
—
—
7
53
214
2149
—
—
—
—
—
—
felodipine; oral
C08CA02 [21601748]
C08CA02 [21601748]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
R03AL11 [715850]
—
—
—
—
—
—
5.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.69%
—
—
—
—
—
—
5
31
176
1806
Combined first trimester screening
MA3AE [2001306839]
MA3AE [2001306839]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
0
13
221
2189
0
9
221
2193
—
—
—
—
—
Extensive CT of neck arteries
PA6BD [2001308697]
PA6BD [2001308697]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2191
—
—
—
—
—
—
Proctoscopy
UJG02 [2001305126]
UJG02 [2001305126]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
Iron deficiency anaemia secondary to blood loss (chronic)
D50.0 [45566697]
D50.0 [45566697]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.27%
—
—
—
—
—
0
5
217
2179
0
5
181
1832
Sialoadenitis
K11.2 [45586705]
K11.2 [45586705]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
6
221
2196
—
—
—
—
—
0
5
181
1832
Iron deficiency anaemia
D50 [45571628]
D50 [45571628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
181
1830
androstanolone
A14AA01 [21600917]
A14AA01 [21600917]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.50%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.54%
0
11
221
2191
0
6
221
2196
—
—
—
0
7
217
2177
0
10
181
1827
Kuhnt-Junius degeneration
H35.30 [2000502314]
H35.30 [2000502314]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
8
217
2176
—
gestodene and ethinylestradiol
G03AA10 [21602483]
G03AA10 [21602483]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
6
217
2178
—
Femur X-ray examination
NF3AA [2001307907]
NF3AA [2001307907]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
181
1831
Skin Pathology biopsy report
65754-4 [40768443]
65754-4 [40768443]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
tetracycline; oral, parenteral
J01AA07 [21602805]
J01AA07 [21602805]
3.0e-01
-1.0e+50
—
—
—
—
—
cases:2.26%
controls:1.68%
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
5
37
216
2165
0
11
221
2191
—
—
—
—
—
Guidance for breast-feeding and breast care
SPAT1200 [2001700301]
SPAT1200 [2001700301]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
9
221
2193
—
—
—
—
—
0
6
181
1831
Type 1 diabetes mellitus, Without complications
E10.9 [45581351]
E10.9 [45581351]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
0
18
221
2183
—
—
Weight-bearing X-ray of foot
NH3FA [2001308284]
NH3FA [2001308284]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Band form neutrophils/Leukocytes in Blood
26508-2 [3004809]
26508-2 [3004809]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
Mitral (valve) prolapse
I34.1 [45552788]
I34.1 [45552788]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
0
5
221
2197
—
—
—
—
—
Extraction of multiple teeth
EBA15 [2001301927]
EBA15 [2001301927]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
2874-6 [3023465]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:0.82%
—
—
—
—
—
—
7
15
174
1822
Carpal tunnel syndrome
G56.0 [45566891]
G56.0 [45566891]
7.0e-01
—
—
—
—
—
—
cases:2.71%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
30
215
2172
—
—
—
—
—
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
C01DA02 [21600317]
—
—
-1.0e+50
—
—
—
-9.7e-02
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:3.87%
controls:4.25%
—
—
0
8
221
2194
—
—
—
7
78
174
1759
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
J01MA02 [21603009]
1.3e-02
4.9e-01
—
—
—
8.3e-01
1.9e-01
cases:5.88%
controls:5.81%
cases:2.71%
controls:1.68%
—
—
—
—
—
—
cases:3.69%
controls:1.65%
cases:5.52%
controls:4.63%
13
128
208
2074
6
37
215
2165
—
—
—
8
36
209
2148
10
85
171
1752
Functional dyspepsia
K30 [45591584]
K30 [45591584]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
9
217
2175
—
Occupational Medicine Clinic/Center
261QX0100X [38004267]
261QX0100X [38004267]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
Laboratory test
15220000 [4034850]
15220000 [4034850]
3.6e-01
—
—
—
—
-1.0e+50
—
cases:2.71%
controls:1.91%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
6
42
215
2160
—
—
—
—
0
25
217
2159
—
Melanocytic naevi, unspecified
D22.9 [45571603]
D22.9 [45571603]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
0
6
221
2196
—
—
—
—
—
oxcarbazepine; oral
N03AF02 [21604418]
N03AF02 [21604418]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.23%
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.44%
0
5
221
2197
0
5
221
2197
—
—
—
0
6
217
2178
0
8
181
1829
clobetasol
D07AD01 [21602141]
D07AD01 [21602141]
7.3e-01
1.8e+00
—
—
—
—
5.4e-01
cases:3.62%
controls:1.77%
cases:2.71%
controls:0.45%
—
—
—
—
—
—
—
—
cases:3.87%
controls:2.29%
8
39
213
2163
6
10
215
2192
—
—
—
—
7
42
174
1795
Single live birth
Z37.0 [45571346]
Z37.0 [45571346]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.93%
—
—
—
—
—
0
8
217
2176
0
17
181
1820
Hand and fingers X-ray examination
ND2AA [2001307607]
ND2AA [2001307607]
1.4e+00
-1.0e+50
—
—
—
—
—
cases:2.26%
controls:0.59%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
5
13
216
2189
0
8
221
2194
—
—
—
—
—
Presbycusis
H91.1 [45591444]
H91.1 [45591444]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
8
221
2194
—
—
—
—
0
5
217
2179
—
Bacteria identified in Cerebral spinal fluid by Culture
606-4 [3016914]
606-4 [3016914]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
181
1832
Other complicated additional procedure necessary for restorative treatment
SFC92 [2001310370]
SFC92 [2001310370]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
217
2179
—
pindolol; oral, parenteral
C07AA03 [21601669]
C07AA03 [21601669]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
N04AB02 [21604458]
2.2e-01
9.7e-01
—
—
—
1.0e+00
5.6e-01
cases:8.60%
controls:7.04%
cases:4.98%
controls:1.95%
—
—
—
—
—
—
cases:5.53%
controls:2.11%
cases:10.50%
controls:6.26%
19
155
202
2047
11
43
210
2159
—
—
—
12
46
205
2138
19
115
162
1722
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
76080-1 [46235759]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
Electrophysiological investigation
TFP34 [2001303229]
TFP34 [2001303229]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
0
5
217
2179
—
Endoscopic polypectomy in colon
JFA15 [2001304850]
JFA15 [2001304850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.50%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
221
2191
—
—
—
—
—
—
Supervision of normal pregnancy, unspecified
Z34.9 [45566420]
Z34.9 [45566420]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
0
8
221
2194
—
—
—
0
5
217
2179
—
Cathetrisation of artery
TPH07 [2001309747]
TPH07 [2001309747]
9.3e-01
—
—
—
—
—
—
cases:2.71%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
—
—
6
24
215
2178
—
—
—
—
—
—
rubella, live attenuated
J07BJ01 [21601359]
J07BJ01 [21601359]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
6
217
2178
—
fenofibrate; oral
C10AB05 [21601869]
C10AB05 [21601869]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
0
5
221
2197
—
—
—
—
0
5
217
2179
—
triamcinolone and antiinfectives
S02CA04 [21605176]
S02CA04 [21605176]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
Recurrent depression, moderate episode without somatic syndrome
F33.10 [2000501984]
F33.10 [2000501984]
1.2e+00
—
—
—
—
—
—
cases:2.26%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
5
16
216
2186
—
—
—
—
—
—
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
SPAT1156 [2001700257]
6.1e-01
-1.0e+50
—
—
—
—
—
cases:2.71%
controls:1.50%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
6
33
215
2169
0
17
221
2185
—
—
—
—
—
dorzolamide
S01EC03 [21603695]
S01EC03 [21603695]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
10
181
1827
Ultrasound screening of fetal nuchal translucency
MA2JE [2001306837]
MA2JE [2001306837]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
Allergic rhinitis
R97 [2002000962]
R97 [2002000962]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
7
181
1830
Venereal disease screening
171128005 [4064905]
171128005 [4064905]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
8
221
2194
—
—
—
—
—
Musculoskeletal disease other
L99 [2002000718]
L99 [2002000718]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
0
5
221
2197
—
—
—
—
—
0
5
181
1832
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
SHB00 [2001310410]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
Corneal ulcer
H16.0 [45557339]
H16.0 [45557339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
221
2190
—
—
—
—
—
—
Fracture of upper end of tibia
S82.1 [45579358]
S82.1 [45579358]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
181
1832
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
N02BE51 [21604348]
6.1e-02
—
—
—
—
9.4e-01
3.1e-01
cases:4.52%
controls:4.27%
—
—
—
—
—
—
—
—
cases:2.30%
controls:0.92%
cases:4.42%
controls:3.27%
10
94
211
2108
—
—
—
—
5
20
212
2164
8
60
173
1777
Tobacco abuse
P17 [2002000813]
P17 [2002000813]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
0
5
181
1832
Lumbago with sciatica
M54.4 [45553205]
M54.4 [45553205]
1.1e+00
—
—
—
—
—
7.1e-01
cases:4.98%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
cases:4.42%
controls:2.23%
11
39
210
2163
—
—
—
—
—
8
41
173
1796
Removal of sutures from oral mucosa
SXB00 [2001310580]
SXB00 [2001310580]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
221
2186
—
—
—
—
—
—
tretinoin; ointment
D10AD01 [21602293]
D10AD01 [21602293]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
221
2187
—
—
—
—
—
—
Cardiology
6 [38004451]
6 [38004451]
3.2e-01
1.4e-01
—
—
—
-2.1e-01
2.0e-01
cases:11.76%
controls:8.81%
cases:4.52%
controls:3.95%
—
—
—
—
—
—
cases:3.23%
controls:3.94%
cases:10.50%
controls:8.76%
26
194
195
2008
10
87
211
2115
—
—
—
7
86
210
2098
19
161
162
1676
fluticasone furoate
R03BA09 [45893496]
R03BA09 [45893496]
2.3e-01
8.7e-01
-1.0e+50
—
-1.0e+50
—
6.7e-01
cases:4.07%
controls:3.27%
cases:3.62%
controls:1.54%
cases:0.00%
controls:0.45%
—
—
cases:0.00%
controls:0.41%
—
—
cases:4.97%
controls:2.61%
9
72
212
2130
8
34
213
2168
0
10
221
2192
—
0
9
221
2192
—
9
48
172
1789
hydrochlorothiazide; oral
C03AA03 [21601466]
C03AA03 [21601466]
1.3e-01
—
—
—
-1.0e+50
—
1.7e-01
cases:2.26%
controls:2.00%
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
cases:2.76%
controls:2.34%
5
44
216
2158
—
—
—
0
5
221
2196
—
5
43
176
1794
desonide
D07AB08 [21602112]
D07AB08 [21602112]
—
—
—
—
—
—
8.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:1.20%
—
—
—
—
—
—
5
22
176
1815
Opiates [Presence] in Urine
3879-4 [3027008]
3879-4 [3027008]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.87%
controls:1.09%
—
—
—
—
—
—
7
20
174
1817
Rash and other nonspecific skin eruption
R21 [45553721]
R21 [45553721]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
0
8
221
2194
—
—
—
—
—
0
6
181
1831
Atrioventricular block, second degree
I44.1 [45543177]
I44.1 [45543177]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
0
6
221
2196
—
—
—
—
0
6
181
1831
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
F32.2 [45557202]
1.3e+00
—
—
—
—
-1.0e+50
—
cases:2.71%
controls:0.73%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
6
16
215
2186
—
—
—
—
0
5
217
2179
—
dexamethasone
S03BA01 [21605201]
S03BA01 [21605201]
3.6e-01
-1.0e+50
—
—
—
-1.0e+50
-4.5e-02
cases:2.26%
controls:1.59%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:2.76%
controls:2.89%
5
35
216
2167
0
20
221
2182
—
—
—
0
23
217
2161
5
53
176
1784
Persons encountering health services for other counselling and medical advice, not elsewhere classified
Z71 [45585850]
Z71 [45585850]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
9
181
1828
Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay
35333-4 [3036086]
35333-4 [3036086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
—
Insulin [Units/volume] in Serum or Plasma
20448-7 [3016244]
20448-7 [3016244]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
221
2194
—
—
—
—
—
—
hydrocortisone; local oral
A01AC03 [21600036]
A01AC03 [21600036]
4.5e-01
—
—
—
—
—
—
cases:2.26%
controls:1.45%
—
—
—
—
—
—
—
—
—
—
—
—
5
32
216
2170
—
—
—
—
—
—
Puncture of maxillary antrum
TDM10 [2001301819]
TDM10 [2001301819]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
221
2192
—
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
L15 [2002000639]
3.8e-01
—
—
—
—
—
5.7e-01
cases:3.62%
controls:2.50%
—
—
—
—
—
—
—
—
—
—
cases:6.08%
controls:3.54%
8
55
213
2147
—
—
—
—
—
11
65
170
1772
Hearing loss, unspecified
H91.9 [45547996]
H91.9 [45547996]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
dexamethasone
S01BA01 [21603618]
S01BA01 [21603618]
3.6e-01
-1.0e+50
—
—
—
-1.0e+50
-4.5e-02
cases:2.26%
controls:1.59%
cases:0.00%
controls:0.91%
—
—
—
—
—
—
cases:0.00%
controls:1.05%
cases:2.76%
controls:2.89%
5
35
216
2167
0
20
221
2182
—
—
—
0
23
217
2161
5
53
176
1784
Other senile cataract
H25.8 [45605644]
H25.8 [45605644]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
5
221
2197
—
—
—
0
8
217
2176
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
J07BA01 [21601331]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
Counselling related to known health issue
SPAT1310 [2001700411]
SPAT1310 [2001700411]
2.6e-01
—
-1.0e+50
—
—
6.5e-01
7.4e-01
cases:7.24%
controls:5.68%
—
—
cases:0.00%
controls:0.23%
—
—
—
—
cases:2.76%
controls:1.47%
cases:8.29%
controls:4.14%
16
125
205
2077
—
0
5
221
2197
—
—
6
32
211
2152
15
76
166
1761
Myalgia
M79.1 [45587062]
M79.1 [45587062]
—
—
—
—
—
—
6.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.31%
controls:1.74%
—
—
—
—
—
—
6
32
175
1805
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
8.3e-02
-1.4e-01
—
—
—
1.5e-01
2.2e-01
cases:4.52%
controls:4.18%
cases:2.26%
controls:2.59%
—
—
—
—
—
—
cases:3.23%
controls:2.79%
cases:7.73%
controls:6.31%
10
92
211
2110
5
57
216
2145
—
—
—
7
61
210
2123
14
116
167
1721
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
57778-3 [40760888]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
0
6
181
1831
Chronic hypertension
205 [2001600203]
205 [2001600203]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
Fibromyalgia
M79.7 [45553272]
M79.7 [45553272]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.76%
controls:0.44%
—
—
—
—
—
—
5
8
176
1829
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
50949-7 [3029937]
-1.0e-01
5.8e-01
1.7e+00
—
—
3.3e-01
5.8e-02
cases:5.43%
controls:5.99%
cases:4.98%
controls:2.86%
cases:2.26%
controls:0.41%
—
—
—
—
cases:4.15%
controls:3.02%
cases:8.84%
controls:8.38%
12
132
209
2070
11
63
210
2139
5
9
216
2193
—
—
9
66
208
2118
16
154
165
1683
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
R5110 [2001310246]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
6
221
2196
—
—
—
—
—
Examination of ears and hearing
Z01.1 [45547279]
Z01.1 [45547279]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
0
6
217
2178
—
Hordeolum
H00.00 [2000502235]
H00.00 [2000502235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
0
10
181
1827
IgG subclass 3 [Mass/volume] in Serum
2468-7 [3024139]
2468-7 [3024139]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Insertion of nasogastric or naso-gastroduodenal tube
TJD00 [2001304797]
TJD00 [2001304797]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
221
2195
—
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
R01AD09 [21605051]
-7.8e-02
-3.6e-01
—
—
—
1.3e-01
3.2e-01
cases:7.69%
controls:8.27%
cases:2.71%
controls:3.86%
—
—
—
—
—
—
cases:3.69%
controls:3.25%
cases:11.05%
controls:8.27%
17
182
204
2020
6
85
215
2117
—
—
—
8
71
209
2113
20
152
161
1685
Systematic individual therapy, cognitive-behavioural
IDY03 [2001304164]
IDY03 [2001304164]
—
-1.0e+50
—
—
—
-1.0e+50
1.2e+00
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
cases:2.76%
controls:0.82%
—
0
5
221
2197
—
—
—
0
7
217
2177
5
15
176
1822
Topography assessment of cornea
CG2T4 [2001301222]
CG2T4 [2001301222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the long-term prevention of recurrent deep veinthrombosis and pulmonary embolism
379 [2001600340]
379 [2001600340]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.23%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
221
2197
—
—
—
—
—
—
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
250
2.06
4.21
9.5
8.7
105.09
103.97
mmol/l
0.78
46
250
21
91
2.44
3.29
1.7
1.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
44
3.07
3.19
3.5
3.5
0.34
0.38
iu/ml
—
7
22
56
357
1.76
3.12
3.6
3.3
59.35
364.58
ng/l
1.58
43
260
95
698
1.63
3.11
4.8
3.4
54.78
31.62
u/l
0.51
90
668
49
303
1.79
3.02
2.1
2.0
—
—
—
0
0
117
910
1.60
3.00
3.3
2.8
—
—
estimate
—
0
0
113
876
1.59
2.91
11.2
8.1
1.20
1.21
mmol/l
0.45
102
768
38
220
1.88
2.88
10.7
8.7
1.08
0.88
mmol/l
0.13
32
179
106
811
1.58
2.88
3.0
2.5
72.60
73.19
nmol/l
0.09
100
734
68
470
1.64
2.79
2.7
2.4
—
—
—
0
0
165
1409
1.65
2.75
3.9
4.1
10.20
10.58
mm/h
0.16
158
1321
6
10
6.13
2.71
1.7
1.5
—
—
—
0
0
10
30
3.44
2.64
1.1
1.4
—
—
—
0
0
10
30
3.44
2.64
1.1
1.4
—
—
—
0
0
33
189
1.87
2.59
12.0
9.6
116.24
123.11
g/l
1.19
33
183
72
514
1.59
2.57
1.7
1.7
21.87
20.81
nmol/l
0.30
59
439
68
479
1.60
2.56
3.1
3.4
3800.23
1160.26
ng/l
0.60
60
401
23
117
2.08
2.51
2.2
1.5
0.33
0.41
mg/l
0.23
15
49
15
64
2.44
2.44
2.1
2.1
—
—
—
0
0
44
281
1.70
2.41
3.7
3.1
1.50
1.88
e6/l
0.15
18
137
62
436
1.58
2.33
1.9
1.9
0.89
1.26
mg/l
0.99
52
346
42
268
1.70
2.31
2.5
2.5
28.80
29.46
s
0.43
42
263
38
238
1.72
2.23
1.9
1.8
—
—
—
0
0
25
138
1.91
2.20
12.0
10.4
24.52
24.80
mmol/l
0.17
25
138
21
109
2.02
2.19
12.3
9.3
15.21
15.80
%
0.58
21
103
14
62
2.34
2.12
1.9
1.7
—
—
—
0
0
30
178
1.79
2.12
3.6
3.1
—
—
—
0
0
36
227
1.70
2.07
2.1
1.9
—
—
—
0
0
64
469
1.51
1.98
2.6
2.1
2.59
2.73
mg/l
0.22
56
413
43
288
1.61
1.97
2.1
2.2
—
—
—
0
0
205
1905
1.90
1.95
21.7
14.7
21.56
22.42
mg/l
0.17
181
1573
68
510
1.48
1.87
4.0
3.2
0.40
0.29
e6/l
0.26
50
358
189
1729
1.60
1.77
6.7
5.9
39.53
38.79
mmol/mol
0.50
182
1649
6
18
3.39
1.76
2.7
1.2
—
—
—
0
0
45
315
1.54
1.71
2.2
2.3
—
—
—
0
0
22
128
1.80
1.67
3.6
2.7
81.70
66.27
ml/min/173m2
—
10
55
72
563
1.41
1.56
4.2
4.3
4.54
13.09
mg/mmol
2.28
49
377
111
936
1.37
1.52
3.5
3.1
121.80
104.97
ug/l
0.59
105
889
16
90
1.84
1.37
3.2
2.3
12350.62
5562.17
u/l
—
9
33
5
17
2.98
1.36
3.6
1.5
—
—
—
0
0
43
314
1.46
1.34
3.8
3.0
0.74
0.90
e6/l
0.27
17
170
209
1990
1.75
1.28
25.7
18.1
80.04
77.15
umol/l
0.52
209
1971
15
85
1.82
1.26
6.3
5.3
1.83
1.64
%
0.31
15
77
74
607
1.33
1.16
4.1
3.3
2.34
2.35
mmol/l
0.32
67
551
127
1122
1.30
1.16
9.8
10.6
4.45
4.12
e9/l
0.83
107
992
119
1045
1.30
1.12
5.1
3.7
0.00
0.00
estimate
-0.00
23
182
5
21
2.41
1.09
1.4
1.8
—
—
—
0
0
5
21
2.41
1.09
1.4
1.8
—
—
—
0
0
5
21
2.41
1.09
1.4
1.8
—
—
—
0
0
117
1030
1.28
1.07
5.2
3.6
0.00
0.00
estimate
-0.00
25
195
184
1722
1.38
1.06
6.3
5.1
1.82
1.85
mu/l
0.13
176
1596
25
172
1.51
1.05
2.2
2.7
28.94
30.70
u/l
0.14
17
140
60
485
1.32
1.03
3.2
3.0
343.29
341.65
umol/l
0.04
51
435
9
47
1.95
1.03
1.4
1.5
—
—
—
0
0
215
2082
1.81
1.03
31.7
22.4
251.63
250.80
e9/l
0.06
210
2052
117
1034
1.28
1.02
5.2
3.7
0.00
0.00
estimate
-0.00
24
195
90
772
1.28
0.99
2.2
2.0
98.73
94.92
pmol/l
0.29
51
402
5
23
2.20
0.98
1.0
1.2
—
—
—
0
0
153
1403
1.29
0.96
5.9
3.4
61.70
48.61
u/l
0.99
147
1336
9
51
1.80
0.95
2.2
2.8
51.44
41.34
mg/l
—
9
43
9
51
1.80
0.95
2.1
2.8
45.01
28.55
mg/l
—
9
43
48
380
1.33
0.95
1.2
1.3
10.96
24.10
iu/ml
2.01
12
107
187
1769
1.35
0.88
20.7
13.6
86.68
86.15
ml/min/173m2
0.12
173
1617
11
64
1.76
0.88
3.6
2.7
—
—
—
0
0
148
1360
1.26
0.87
3.5
3.4
—
—
—
0
0
8
44
1.85
0.87
1.6
1.2
—
—
—
0
0
18
121
1.53
0.86
1.2
1.3
20.28
20.70
iu/l
0.02
13
108
16
105
1.56
0.84
1.3
1.4
—
—
—
0
0
186
1762
1.33
0.83
5.3
4.7
6.11
5.89
mmol/l
1.18
177
1633
7
38
1.87
0.74
1.1
1.2
—
—
—
0
0
13
193
0.65
0.73
2.1
1.8
4.09
3.52
mmol/l
—
8
135
42
340
1.29
0.72
1.2
1.3
5.35
5.87
u/ml
0.04
20
136
68
586
1.23
0.70
5.3
2.9
0.00
0.01
estimate
0.50
21
164
7
42
1.69
0.69
1.7
1.8
—
—
—
0
0
5
27
1.87
0.69
1.4
2.0
—
—
—
0
0
18
128
1.44
0.68
8.6
5.0
2.97
1.33
mmol/l
—
9
99
154
1441
1.22
0.67
5.6
4.3
14.79
14.68
pmol/l
0.25
148
1326
79
695
1.21
0.66
5.1
3.6
34.40
32.83
ng/l
0.04
59
458
184
1756
1.27
0.65
4.5
4.1
1.35
1.30
mmol/l
0.43
177
1646
19
138
1.41
0.65
2.1
1.5
—
—
—
0
0
194
1864
1.30
0.65
5.9
5.3
2.73
2.74
mmol/l
0.07
188
1757
191
1832
1.29
0.64
5.2
4.7
1.37
1.41
mmol/l
0.93
183
1723
5
29
1.74
0.64
1.2
1.2
—
—
—
0
0
0
20
0.00
0.60
0.0
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
78
692
1.20
0.59
5.2
4.8
1.68
1.88
ug/l
0.38
70
626
6
35
1.73
0.58
1.0
1.1
—
—
—
0
0
17
124
1.40
0.57
11.2
7.7
24.16
24.52
mmol/l
0.18
17
117
6
36
1.68
0.57
3.0
6.1
—
3914.57
—
0
7
87
782
1.18
0.57
5.1
3.5
0.00
0.02
estimate
0.74
18
168
10
66
1.54
0.53
1.2
1.7
0.27
0.24
g/l
—
10
66
48
413
1.21
0.50
2.8
2.9
0.77
0.75
ug/l
0.06
28
244
10
68
1.49
0.48
1.5
1.4
—
—
—
0
0
33
276
1.23
0.45
1.6
1.5
—
—
—
0
0
7
50
1.41
0.45
1.4
1.6
—
—
—
0
0
13
95
1.39
0.45
1.4
1.3
—
—
—
0
0
20
158
1.29
0.43
2.3
2.0
—
—
—
0
0
5
31
1.63
0.43
1.4
1.9
—
—
—
0
0
8
57
1.42
0.42
1.5
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.48
0.40
3.2
3.4
4.54
10.05
pmol/l
—
5
34
0
19
0.00
0.39
0.0
4.4
—
102.14
—
0
19
52
463
1.16
0.38
1.8
1.7
—
—
—
0
0
9
69
1.32
0.37
1.2
1.5
—
—
—
0
0
9
70
1.30
0.37
1.4
1.7
—
—
—
0
0
6
41
1.48
0.36
1.5
1.5
—
—
—
0
0
6
42
1.44
0.36
1.3
1.9
—
—
—
0
0
6
42
1.44
0.36
1.5
1.6
—
—
—
0
0
21
253
0.81
0.35
2.1
2.0
3.50
3.55
ratio
0.05
15
200
7
57
1.24
0.29
1.4
1.5
52.28
49.37
ug/l
—
7
57
7
57
1.24
0.29
1.1
1.3
—
—
—
0
0
7
57
1.24
0.29
1.9
1.4
—
—
—
0
0
8
64
1.26
0.28
1.4
1.8
—
—
—
0
0
62
572
1.12
0.27
6.2
3.6
0.00
0.01
estimate
0.50
23
184
5
72
0.69
0.26
1.0
1.2
—
12.24
—
0
9
10
78
1.30
0.24
1.9
1.7
160.50
237.71
pmol/l
—
10
72
15
125
1.21
0.23
1.2
1.2
—
24.09
—
0
9
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
60
559
1.10
0.22
4.1
4.4
21.51
21.88
%
0.04
25
250
21
182
1.17
0.22
2.5
2.2
—
—
—
0
0
5
41
1.22
0.22
1.4
2.4
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
210.40
—
0
10
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
9.42
—
0
12
0
12
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
10
80
1.26
0.21
1.4
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
83
788
1.08
0.20
1.8
1.9
1.40
1.40
mmol/l
0.02
65
682
0
14
0.00
0.20
0.0
1.0
—
617.00
—
0
8
0
14
0.00
0.20
0.0
1.0
—
35.43
—
0
7
17
146
1.18
0.20
1.1
1.2
147.42
137.48
u/ml
—
6
58
6
51
1.18
0.19
1.3
1.5
—
—
—
0
0
6
52
1.16
0.19
1.2
1.6
—
—
—
0
0
7
62
1.13
0.17
2.4
1.8
—
—
—
0
0
6
76
0.78
0.16
1.3
1.5
1.58
3.87
mg/l
—
6
58
11
96
1.15
0.10
1.2
1.1
0.86
0.90
g/l
0.24
11
96
6
57
1.05
0.08
1.3
1.3
—
—
—
0
0
6
57
1.05
0.08
1.0
1.5
—
—
—
0
0
6
58
1.04
0.08
1.3
1.3
—
—
—
0
0
5
62
0.80
0.08
1.0
1.2
—
—
—
0
0
7
64
1.10
0.08
1.4
1.5
—
—
—
0
0
7
84
0.83
0.07
1.1
2.1
39.29
40.58
u/l
—
7
73
47
461
1.02
0.02
5.5
3.8
1.02
1.02
kg/l
0.64
37
301
11
117
0.94
0.02
1.0
1.0
—
—
—
0
0
20
196
1.02
0.00
13.6
7.3
—
—
—
0
0
51
506
1.01
0.00
1.3
1.3
0.59
1.34
u/ml
1.44
19
135
11
106
1.04
0.00
1.6
1.4
—
—
—
0
0
16
156
1.03
0.00
1.6
1.4
—
—
—
0
0
10
95
1.06
0.00
5.4
2.0
—
—
—
0
0
10
95
1.06
0.00
1.0
1.1
1.61
1.54
g/l
—
10
95
5
50
1.00
0.00
7.8
3.8
6.74
13.47
umol/l
—
5
41
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.6
—
—
—
0
0
7
75
0.93
-0.00
1.3
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
1.0
—
139.00
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
0.25
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
1273.88
—
0
8
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.1
—
52.29
—
0
7
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
5.4
—
60.42
—
0
5
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
66
0.91
-0.00
1.5
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
44.33
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ST19_BURN_CORROSION_BODY_REGION_UNSPE – Burn and corrosion, body region unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).